mo:re GmbH

What mo:re GmbH does

mo:re GmbH is a Hamburg-based lab automation company developing the MO:BOT, a modular benchtop platform that automates 3D cell culture workflows for organoid and spheroid-based drug discovery and preclinical research. Founded in 2023 and incorporated as a GmbH (HRB 180257), the company operates from a 320 m² integrated facility combining a biology lab, office, and prototype workshop, supported by a 12-person team spanning biology, engineering, software, and commercial functions. The MO:BOT integrates robotic liquid handling, real-time deep-learning imaging (MO:CROSCOPE), and plug-and-play hardware modules (MO:HEAT, MO:COOL, MO:SHAKE, MO:TILT) to automate cell seeding, medium exchange, compound dosing, imaging, and endpoint assays across 9 pre-verified organoid types, with positive displacement pipetting engineered to handle delicate 3D structures without aspiration damage.

The platform's primary technical differentiator is the integration of gentle organoid handling, standardized pre-verified biological protocols, and audit-grade data capture in a single regulated-workflow-ready system, with software generating timestamped experimental logs and regulatory-grade reports aligned with 21 CFR Part 11, FDA NAM Roadmap, and ISO/AWI 25430-2 standards. mo:re sells or leases MO:BOT as a hardware-software-protocol bundle on a quote-based enterprise model with multi-year contracts, supported by co-development partnerships with assay and reagent vendors (Promega, Revvity, ACROBiosystems) and validation collaborations with research institutions (Fraunhofer ITMP Hamburg, Organo Therapeutics, UKE). The product officially launched at SLAS 2025 in San Diego and received the 2025 SLAS New Product Award at SLAS Europe, backed by a €2.3 million seed round led by HTGF (High-Tech Gründerfonds) in March 2025.

Name

mo:re GmbH

Legal name

mo:re GmbH

Website

https://more.science

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

mo:re GmbH develops the MO:BOT, a modular benchtop platform that automates 3D cell culture workflows for organoid-based drug discovery, serving pharmaceutical companies, biotech firms, academic research institutions, and CROs conducting preclinical and toxicology research.

Ownership category

akta.pro rank

Product category

Lab Automation Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Apparatus & Furniture (3821), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• 3D cell culture automation
• Organoid culture platforms
• Lab automation robotics
• Drug discovery instruments
• Preclinical research tools

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. MO:BOT Platform and Software: The company sells or leases its automated MO:BOT hardware platform along with associated software and validated protocol packages to pharmaceutical companies, biotech firms, research institutions, and CROs. Revenue is derived from platform hardware sales/leases, software licensing, and protocol packages for 3D cell culture automation in drug discovery and preclinical research.
2. Validated Organoid Protocol Kits: MO:BOT Kit offerings including ready-to-use organoid differentiation protocols (e.g., human cortical organoid derived from iPSCs) bundled with the platform. Additional revenue from specialized reagent and consumable packages optimized for the automated workflow.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

mo:re GmbH develops and sells the MO:BOT, a benchtop automated platform for 3D cell culture (organoids and spheroids) that integrates modular robotics, real-time imaging (MO:CROSCOPE), environmental modules (MO:HEAT, MO:COOL, MO:SHAKE, MO:TILT), and pre-verified biological protocols to automate cell seeding, media exchange, compound dosing, imaging, and endpoint assays for drug discovery and disease modeling customers.

Product overview

mo:re GmbH offers the MO:BOT platform, a modular automated system for 3D cell culture production. The core MO:BOT platform integrates with specialized modules including MO:CROSCOPE (quality control imaging), MO:HEAT (heating), MO:COOL (cooling), MO:SHAKE (shaking), and MO:TILT (tilting). The MO:BOT Kit provides pre-verified protocols for 9 organoid types, while the MO:BOT Software delivers auditable reports for regulatory submissions. The platform connects to third-party assays including Promega's CellTiter-Glo 3D, Revvity's ATPlite, and ACROBiosystems' organoid reagents for end-to-end automated workflows in drug discovery, toxicology, and disease modeling.

Differentiator

Problem solved

Functional benefit

Brands

• MO:BOT: Automated 3D cell culture platform that automates cell seeding, media exchange, imaging, and data acquisition for organoid and spheroid workflows
• MO:CROSCOPE
• MO:HEAT
• MO:COOL
• MO:SHAKE
• MO:TILT

Products and services

• MO:BOT Platform Benchtop automated 12-plate (SLAS/SBS format) platform that integrates robotics, modular hardware, imaging, and validated biological protocols to automate organoid and spheroid culture workflows including cell seeding, medium exchange, compound dosing, and imaging. Targeted at pharmaceutical companies, biotech firms, academic research institutions, and CROs.
• MO:CROSCOPE Real-time quality control imaging module that analyzes morphologic characteristics of organoids and spheroids during standard handling steps, with onboard deep learning-based analysis for automated phenotypic readouts and sample selection.
• MO:HEAT Heating module capable of up to 40°C for sample incubation and chemical reactions. Modular, plug-and-play component with automatic recognition on the MO:BOT platform.
• MO:COOL Cooling module capable of down to -5°C for sensitive experiments and sample storage. Modular, plug-and-play component with automatic recognition on the MO:BOT platform.
• MO:SHAKE Shaking module up to 1,000 rpm for rigorous mixing and homogenous reactions. Modular, plug-and-play component for the MO:BOT platform.
• MO:TILT Tilting module for gentle mixing, enhanced medium exchange, and distribution of cells or reagents. Modular, plug-and-play component for the MO:BOT platform with automatic recognition.
• MO:BOT Kit Protocol kit for generating organoids and spheroids, including pre-verified biological protocols for 9 different organoid types with ready-to-use differentiation methods integrated within the MO:BOT system.
• MO:BOT Software Software interface enabling experiment setup and launch in under 15 minutes without scripting; provides timestamped experimental logs with integrated QC, imaging, and analysis data, generating complete and auditable reports suitable for regulatory submissions including IND.

Quantifiable outcome

• Automated medium exchanges preserve organoid morphology (under 5% area loss vs. over 15% with manual handling) and maintain significantly higher ATP/viability levels compared to manual culture.
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• ACROBiosystemscoreStrategic or Co-development Partner · 10 February 2026mo:re and ACROBiosystems integrated ACROBiosystems' organoid reagent portfolio (cardiac organoid differentiation reagents, maintenance reagents, validated antibodies) into MO:BOT automated workflows. The collaboration enables end-to-end, standardized cardiac organoid generation and characterization, supporting non-animal drug development and cardiotoxicity testing.
• RevvitycoreStrategic or Co-development Partner · 28 January 2026mo:re and Revvity entered a collaboration to improve reproducibility in 3D cell model research by integrating MO:BOT's automated spheroid generation with Revvity's ATPlite assay and plate readers. The partnership aims to streamline and automate liver spheroid workflows for toxicity testing, with potential expansion to kidney organoids and other 3D models.
• Organo TherapeuticscoreStrategic or Co-development Partner · 1 September 2024mo:re collaborated with Organo Therapeutics on automated 3D cell culture workflows, demonstrating that automated medium exchanges on MO:BOT preserve organoid morphology and enhance cell viability compared to manual handling. The study showed that after 3 medium exchanges, MO:BOT-cultured organoids lost under 5% area vs. over 15% loss with manual methods.
• Fraunhofer ITMP HamburgcoreStrategic or Co-development Partner · 1 February 2024mo:re collaborated with Fraunhofer ITMP Hamburg on automated medium exchange of iPSC-derived cortical organoids. Results demonstrated that MO:BOT maintained higher organoid viability and consistent morphology (area and roundness) across 60 organoids over 4 automated medium exchanges, with zero organoids aspirated.

Scale indicators4 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• Mimetas: Mimetas offers the OrganoPlate, a microfluidic organoid-on-a-chip platform for high-throughput 3D cell culture and disease modeling. It directly competes with mo:re for pharma/biotech customers automating organoid workflows, though its technology is plate-based microfluidics rather than robotic liquid handling.
• InSphero: InSphero develops 3D microtissue (spheroid) platforms and services for drug discovery and toxicology. Comparable to mo:re in serving preclinical organoid/spheroid applications in pharma, though InSphero emphasizes off-the-shelf 3D models and contract services rather than customer-deployed automation hardware.
• CN Bio: CN Bio provides organ-on-chip platforms (PhysioMimix) for drug discovery and toxicity testing. Direct competitor to mo:re in automating organoid-based preclinical workflows, with a different technical approach (microphysiological systems) targeting similar pharma NAM use cases.
• Emulate: Emulate's Organ-Chip technology automates organoid/organ-on-chip workflows for pharmaceutical R&D. Comparable to mo:re in serving pharma customers seeking scalable, reproducible organoid-based disease modeling and toxicology, with broader commercial scale and FDA engagement.
• BICO (Cellink): BICO (formerly Cellink) is a bioconvergence company providing 3D cell culture, bioprinting, and lab automation tools for organoids and tissue engineering. Overlaps with mo:re in automating 3D cell culture for pharma and academic customers, with broader scope across bioprinting and diagnostics.

Broad incumbents

• Hamilton Company: Hamilton is a leading manufacturer of automated liquid handling robots and lab automation platforms widely used in pharma and biotech. While not purpose-built for organoids, Hamilton's installed base and custom workflow capabilities represent the primary competitive threat from general-purpose incumbents.
• Tecan: Tecan provides laboratory automation platforms, liquid handling, and detection instruments to pharma and academic labs. Represents a broad incumbent competitor that could extend into organoid-specific automation given its customer reach and capital scale.
• Beckman Coulter Life Sciences: Beckman Coulter Life Sciences (part of Danaher) supplies automated liquid handlers, plate handlers, and cell culture automation systems. A broad incumbent with the scale and customer footprint to expand into organoid-specific workflows, posing competitive pressure on mo:re.
• Molecular Devices: Molecular Devices offers high-content imaging and 3D cell culture analysis systems used in pharma drug discovery. Comparable to mo:re in serving organoid/spheroid imaging and analysis use cases, with broader product portfolio and established pharma sales channels.

Others

• Revvity: Revvity (formerly PerkinElmer) supplies life science reagents, assays, and detection instruments — including the ATPlite assay integrated into mo:re's platform. A key ecosystem partner rather than direct competitor, but indicative of the broader reagent/assay vendors whose customers mo:re can access through co-marketed workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/more-lifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about mo:re GmbH